{"id":11550,"date":"2025-07-24T10:17:55","date_gmt":"2025-07-24T08:17:55","guid":{"rendered":"https:\/\/www.sgmo.ch\/prise-de-position-de-la-ssom-concernant-lunsumio\/"},"modified":"2025-07-24T10:17:55","modified_gmt":"2025-07-24T08:17:55","slug":"prise-de-position-de-la-ssom-concernant-lunsumio","status":"publish","type":"post","link":"https:\/\/www.sgmo.ch\/fr\/prise-de-position-de-la-ssom-concernant-lunsumio\/","title":{"rendered":"Prise de position de la SSOM concernant Lunsumio"},"content":{"rendered":"<p class=\"elementtoproof\"><span lang=\"FR-CH\">La SSOM prend note avec inqui\u00e9tude de cet incident sans pr\u00e9c\u00e9dent. M\u00eame s&rsquo;il s&rsquo;agit d&rsquo;un cancer relativement rare (lymphome folliculaire) qui touche relativement peu de patients, cela soul\u00e8ve n\u00e9anmoins une question importante : comment les autorit\u00e9s sanitaires et l&rsquo;industrie pharmaceutique peuvent-elles garantir que la Suisse ne passe pas \u00e0 c\u00f4t\u00e9 de nouveaux traitements efficaces contre le cancer ? Si cet exemple fait \u00e9cole, les personnes atteintes d&rsquo;un cancer r\u00e9sidant en Suisse seraient bient\u00f4t d\u00e9savantag\u00e9es par rapport \u00e0 celles d&rsquo;autres pays. La seule lueur d&rsquo;espoir concernant Lunsumio est que l&rsquo;acc\u00e8s \u00e0 ce traitement reste possible gr\u00e2ce \u00e0 un programme pour les cas de rigueur initi\u00e9 par la SSOM, appel\u00e9 \u00ab Swiss Patient Access Program \u00bb (SPAP). Roche doit fournir gratuitement le m\u00e9dicament dans le cadre du SPAP si deux experts ind\u00e9pendants d\u00e9sign\u00e9s par la SSOM concluent que le traitement par Lunsumio est indiqu\u00e9.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La SSOM prend note avec inqui\u00e9tude de cet incident sans pr\u00e9c\u00e9dent. M\u00eame s&rsquo;il s&rsquo;agit d&rsquo;un cancer relativement rare (lymphome folliculaire) qui touche relativement peu de patients, cela soul\u00e8ve n\u00e9anmoins une [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-11550","post","type-post","status-publish","format-standard","hentry","category-non-classifiee"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/posts\/11550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/comments?post=11550"}],"version-history":[{"count":0,"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/posts\/11550\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/media?parent=11550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/categories?post=11550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sgmo.ch\/fr\/wp-json\/wp\/v2\/tags?post=11550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}